EFTR — Effector Therapeutics Share News
0.000.00%
HealthcareHighly SpeculativeMicro Cap
Brief: Effector Therapeutics On July 31, Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
eFFECTOR Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Effector Therapeutics Raises Total Of $16.2 Mln In Gross Proceeds
Brief: Effector Therapeutics Announces $8.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
U.S. STOCKS ON THE MOVE-Coherent, Copper miners, US banks
U.S. STOCKS ON THE MOVE-Ulta Beauty, Paramount Global, Microsoft
eFFECTOR Therapeutics rises on positive interim data for breast cancer drug
U.S. STOCKS ON THE MOVE-Marvell Technology, Tilray, Workday
Brief: eFFECTOR Therapeutics Announces $7.5 Mln Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
U.S. STOCKS ON THE MOVE-Ford Motor, Gap, Moderna
eFFECTOR Therapeutics rises on positive interim data for breast cancer drug
Brief: Effector Therapeutics Reports Positive Data Updates From Phase 2 Expansion Cohorts Evaluating Zotatifin In Patients With Er+ Metastatic Breast Cancer At The Asco 2023 Annual Meeting
Brief: Effector Therapeutics Inc-On May 17, Co Received Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard From Nasdaq
eFFECTOR Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Effector Therapeutics Reports First Quarter 2023 Financial Results And Provides Corporate Update
eFFECTOR Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Effector Therapeutics To Collaborate With Stanford Medicine On Phase 2 Study In Patients With Breast Cancer
U.S. RESEARCH ROUNDUP-Etsy, Qualtrics International, Tcr2 Therapeutics
Brief: Effector Therapeutics Reports Fourth Quarter And Full Year 2022 Financial Results And Provides Corporate Update